The effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment.

Conclusion: DM and higher HbA1c increased the risk of not achieving therapeutic targets for pyrazinamide (but not rifampicin or isoniazid). Higher pyrazinamide concentrations, though, were associated with worse microbiologic and clinical outcomes. DM status also appeared to influence PK-PD relationships for isoniazid and rifampicin.
PMID: 30126955 [PubMed - as supplied by publisher]

Source: Antimicrobial Agents and Chemotherapy - August 20, 2018 Category: Microbiology Authors: Alfarisi O, Mave V, Gaikwad S, Sahasradubhe T, Ramachandran G, Kumar H, Gupte N, Kulkarni V, Deshmukh S, Atre S, Raskar S, Lokhande R, Barthwal M, Kakrani A, Gupta A, Golub JE, Dooley KE Tags: Antimicrob Agents Chemother Source Type: research